glp-1 and sglt2 combo weight loss
Obesity Treatment Double‑Drug 2026 The Future Starts Now
In an 8-week trial, the GLP-1 and SGLT2 combination achieved a 10% average weight loss, indicating a rapid and clinically meaningful effect for patients with obesity. The regimen pairs semaglutide 2.4 mg with dapagliflozin 10 mg, targeting appetite and renal glucose excretion simultaneously. Early data suggest this double-take therapy